Correlation Between Morgan Stanley and Bellerophon Therapeutics

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Bellerophon Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Bellerophon Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley Direct and Bellerophon Therapeutics, you can compare the effects of market volatilities on Morgan Stanley and Bellerophon Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Bellerophon Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Bellerophon Therapeutics.

Diversification Opportunities for Morgan Stanley and Bellerophon Therapeutics

0.0

Correlation Coefficient

Morgan Stanley  Bellerophon Therapeutics

Pay attention - limited upside

The 3 months correlation between Morgan and Bellerophon is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and Bellerophon Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bellerophon Therapeutics and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with Bellerophon Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bellerophon Therapeutics has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Bellerophon Therapeutics go up and down completely randomly.

Pair Corralation between Morgan Stanley and Bellerophon Therapeutics

If you would invest (100.00) in Bellerophon Therapeutics on December 30, 2024 and sell it today you would earn a total of  100.00  from holding Bellerophon Therapeutics or generate -100.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

Morgan Stanley Direct  vs.  Bellerophon Therapeutics

Morgan Stanley Direct

Risk-Adjusted Performance

Very Weak

Over the last 90 days Morgan Stanley Direct has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent fundamental indicators, Morgan Stanley is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors.

Bellerophon Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Bellerophon Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Bellerophon Therapeutics is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders.

Pair Trading with Morgan Stanley and Bellerophon Therapeutics

The main advantage of trading using opposite Morgan Stanley and Bellerophon Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Bellerophon Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bellerophon Therapeutics will offset losses from the drop in Bellerophon Therapeutics' long position.

The idea behind Morgan Stanley Direct and Bellerophon Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.